Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Alvotech Warrant (ALVOW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/13/2025: ALVOW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -51.51% | Avg. Invested days 37 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/13/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.19 | 52 Weeks Range 1.02 - 4.99 | Updated Date 05/16/2025 |
52 Weeks Range 1.02 - 4.99 | Updated Date 05/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 16.42% | Operating Margin (TTM) 7.97% |
Management Effectiveness
Return on Assets (TTM) 7.02% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 100126591 |
Shares Outstanding - | Shares Floating 100126591 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Alvotech Warrant
Company Overview
History and Background
Alvotech is a biopharmaceutical company focused on the development and manufacture of biosimilar medicines. The Alvotech warrant (ALVO.WS) provides the holder the right to purchase shares of Alvotech, it was issued when Alvotech went public through a SPAC.
Core Business Areas
- Biosimilar Development: Develops biosimilars of complex biologic drugs, focusing on immunology, oncology, and ophthalmology.
- Manufacturing: Operates a state-of-the-art manufacturing facility to produce biosimilars at scale.
- Commercialization: Partners with established pharmaceutical companies to commercialize its products globally.
Leadership and Structure
Robert Wessman is the Founder and Chairman. The company has a typical organizational structure for a biopharmaceutical company, with departments for R&D, manufacturing, commercialization, and finance.
Top Products and Market Share
Key Offerings
- AVT02 (biosimilar adalimumab): A biosimilar to Humira (adalimumab) used to treat autoimmune diseases. Market share depends on regulatory approvals and launch in various regions. Competitors: Amgen's Amjevita, Sandoz's Hyrimoz, Boehringer Ingelheim's Cyltezo.
- AVT04 (biosimilar bevacizumab): A biosimilar to Avastin (bevacizumab) used to treat various cancers. Market share depends on regulatory approvals and launch in various regions. Competitors: Amgen's Mvasi, Pfizer's Zirabev.
Market Dynamics
Industry Overview
The biosimilars market is growing rapidly due to increasing healthcare costs and the expiration of patents on blockbuster biologic drugs.
Positioning
Alvotech is positioned as a key player in the biosimilars market, with a focus on high-value, complex biosimilars. Their advantage is the speed to market and the complexity of products they can manufacture.
Total Addressable Market (TAM)
The global biosimilars market is expected to reach hundreds of billions of dollars. Alvotech is positioning to capture a significant share of this market through strategic partnerships and product development.
Upturn SWOT Analysis
Strengths
- Strong pipeline of biosimilar candidates
- State-of-the-art manufacturing facility
- Strategic partnerships with established pharmaceutical companies
- Experienced management team
Weaknesses
- Dependence on regulatory approvals
- Competition from established pharmaceutical companies
- High R&D costs
- Debt load
Opportunities
- Expanding biosimilars market
- Increasing demand for affordable medicines
- Strategic alliances to expand market access
- New product development
Threats
- Regulatory hurdles
- Price erosion
- Intellectual property disputes
- Competition from new entrants
Competitors and Market Share
Key Competitors
- AMGN
- PFE
- SNY
Competitive Landscape
Alvotech competes with established pharmaceutical companies in the biosimilars market. Alvotech needs to secure regulatory approvals to gain market share.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited as this is a relatively new company.
Future Projections: Future growth depends on regulatory approvals and commercial success of its biosimilar pipeline.
Recent Initiatives: Recent initiatives include regulatory submissions for its biosimilar candidates and partnership agreements for commercialization.
Summary
Alvotech is a promising biosimilar company with a strong pipeline and manufacturing capabilities. Its success depends on its ability to secure regulatory approvals and effectively commercialize its products. The warrant price will be closely correlated with the performance of the underlying common stock. Competition in the biosimilars market is intense, so Alvotech must navigate these dynamics successfully. The company's debt load is a significant risk factor.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The warrant price can be very volatile and investors must do their own due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Alvotech Warrant
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2022-06-16 | CEO, Founder & Executive Chairman Mr. Robert Wessman | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 1012 | Website https://www.alvotech.com |
Full time employees 1012 | Website https://www.alvotech.com | ||
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product for the treatment of adult patients with moderate to severe ulcerative colitis and moderate to severely active Crohn's disease; AVT23, a biosimilar to Xolair to treat allergic asthma, chronic spontaneous urticaria (CSU), and nasal polyp; and AVT33, a biosimilar to Keytruda product which is in early phase development. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.